- Home
- SNBR vs FHTX Comparison
SNBR vs FHTX Comparison
Compare SNBR & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNBR
- FHTX
- Stock Information
- Founded
- SNBR 1987
- FHTX 2015
- Country
- SNBR United States
- FHTX United States
- Employees
- SNBR N/A
- FHTX N/A
- Industry
- SNBR Home Furnishings
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- SNBR Consumer Discretionary
- FHTX Health Care
- Exchange
- SNBR Nasdaq
- FHTX Nasdaq
- Market Cap
- SNBR N/A
- FHTX 517.9M
- IPO Year
- SNBR 1998
- FHTX 2020
- Fundamental
- Price
- SNBR $14.46
- FHTX $7.55
- Analyst Decision
- SNBR Hold
- FHTX Strong Buy
- Analyst Count
- SNBR 3
- FHTX 5
- Target Price
- SNBR $14.17
- FHTX $16.00
- AVG Volume (30 Days)
- SNBR 331.0K
- FHTX 135.3K
- Earning Date
- SNBR 10-30-2024
- FHTX 11-04-2024
- Dividend Yield
- SNBR N/A
- FHTX N/A
- EPS Growth
- SNBR N/A
- FHTX N/A
- EPS
- SNBR N/A
- FHTX N/A
- Revenue
- SNBR $1,781,028,000.00
- FHTX $35,185,000.00
- Revenue This Year
- SNBR N/A
- FHTX N/A
- Revenue Next Year
- SNBR $2.90
- FHTX $15.40
- P/E Ratio
- SNBR N/A
- FHTX N/A
- Revenue Growth
- SNBR N/A
- FHTX 61.95
- 52 Week Low
- SNBR $8.13
- FHTX $2.70
- 52 Week High
- SNBR $21.96
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- SNBR 42.68
- FHTX 45.26
- Support Level
- SNBR $14.08
- FHTX $7.24
- Resistance Level
- SNBR $17.08
- FHTX $8.35
- Average True Range (ATR)
- SNBR 1.09
- FHTX 0.54
- MACD
- SNBR -0.29
- FHTX -0.06
- Stochastic Oscillator
- SNBR 14.73
- FHTX 43.20
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.